{"id":1389,"date":"2018-06-02T21:27:53","date_gmt":"2018-06-02T21:27:53","guid":{"rendered":"https:\/\/grail.wpengine.com\/?post_type=press-release&p=1389"},"modified":"2021-01-16T00:34:21","modified_gmt":"2021-01-16T00:34:21","slug":"grail-announces-data-on-detection-of-early-stage-lung-cancers","status":"publish","type":"press-release","link":"https:\/\/grail.com\/press-releases\/grail-announces-data-on-detection-of-early-stage-lung-cancers\/","title":{"rendered":"GRAIL Announces Data on Detection of Early-Stage Lung Cancers"},"content":{"rendered":"

CHICAGO\u2013(BUSINESS WIRE<\/a>)\u2013GRAIL, Inc., a healthcare company focused on the early detection of cancer, today announced new data from the Circulating Cell-free Genome Atlas (CCGA) study. In a sub-analysis of the first pre-planned sub-study of CCGA, blood samples from 127 participants with lung cancer were evaluated with three prototype genome-sequencing assays. Detection rates (sensitivity at 98 percent specificity) across the assays ranged from 38 to 51 percent in participants with early-stage lung cancer (stages I-IIIA), and 87 to 89 percent in those with later stages (stages IIIB-IV).<\/p>\n

These data will be presented today in a press briefing at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting, and also as an oral presentation on Monday, June 4, 2018 by Geoffrey Oxnard, MD, Associate Professor of Medicine at Dana-Farber Cancer Institute and Harvard Medical School.<\/p>\n

\u201cLung cancer is the single greatest cause of cancer death globally and is typically diagnosed at late stages when, despite recent treatment breakthroughs, survival is often measured in months,\u201d said Dr. Oxnard. \u201cThese initial data from CCGA are exciting because they suggest it is possible to detect lung cancer through DNA signals in the blood at earlier stages when survival rates may be higher.\u201d<\/p>\n

\u201cWe are encouraged by these initial results and believe a highly specific blood test for lung cancer could help improve early detection rates for this deadly disease,\u201d said Anne-Renee Hartman, MD, Vice President of Clinical Development at GRAIL. \u201cLung cancer will be an important focus in our ongoing clinical development program for the early detection of multiple cancer types.\u201d<\/p>\n

More than 154,000 people are expected to die from lung cancer in the United States in 20181<\/sup>\u00a0and approximately 1.7 million globally.2<\/sup>The five-year survival rate for lung cancer overall is 18 percent. The five-year survival rate for early-stage lung cancer is 56 percent; however, only 16 percent of lung cancers are diagnosed at this early stage.1<\/sup><\/p>\n

Additional Results<\/b><\/p>\n

In this pre-planned sub-study of CCGA, three prototype genome-sequencing assays were evaluated as potential methods for a blood-based test for early cancer detection. In the first training phase of the sub-study, blood samples from 1,627 participants with and without cancer were sequenced. Twenty different cancer types across all stages were included in the sub-study.<\/p>\n

For the lung cancer sub-analysis, blood samples from 127 participants with lung cancer were analyzed.<\/p>\n

The prototype sequencing assays included:<\/p>\n